Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282930737> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4282930737 endingPage "284" @default.
- W4282930737 startingPage "277" @default.
- W4282930737 abstract "Infection due to SARS-CoV-2 is associated with clinical features of diverse severity. Severe disease includes biological criteria of both inflammation and coagulation activation, and high circulating levels of pro- and anti-inflammatory cytokines. The most critical patients present with acute respiratory distress syndrome and multiple organ failure, resembling bacterial sepsis. Clinical trials have shown that steroids reduce mortality of severe cases, suggesting that inflammation as a mechanism of defense against viral invasion is excessive rather than insufficient. Several molecules targeting more specific pathways than steroids are under evaluation. Those reducing interleukin 6 activity have a certain degree of effectiveness. Anticoagulants and fibrinolytics have moderate impact on the hypercoagulation state. Like for bacterial sepsis, future trials will attempt therapy individualization based on biomarkers, but we still lack precision diagnostic tools.: L’infection par le virus SARS-CoV-2 entraîne des tableaux de gravité variable. La biologie des formes graves comporte des critères d’inflammation et d’activation de la coagulation, ainsi que la circulation des cytokines pro- et anti-inflammatoires en grande quantité. Les formes les plus sévères comportent un syndrome de détresse respiratoire aiguë, voire une défaillance multiviscérale qui ressemble au sepsis d’origine bactérienne. Les essais thérapeutiques effectués dans ces formes graves indiquent que les corticoïdes en réduisent la mortalité, ce qui suggère que l’état hyper-inflammatoire peut être excessif plutôt qu’insuffisant dans notre défense contre l’infection virale. Plusieurs molécules plus sélectives que les corticoïdes sont à l’étude. Celles qui réduisent l’activité de l’interleukine 6 ont une certaine efficacité. L’état hyper-coagulable est peu influencé par les traitements anti-coagulants ou fibrinolytiques. Comme dans le sepsis bactérien, l’évolution se fera vers plus d’individualisation des traitements à partir de certains biomarqueurs, mais cette pratique se heurte encore à un manque de précision dans les outils diagnostiques." @default.
- W4282930737 created "2022-06-16" @default.
- W4282930737 creator A5015363411 @default.
- W4282930737 creator A5016246504 @default.
- W4282930737 creator A5026753610 @default.
- W4282930737 creator A5035825833 @default.
- W4282930737 creator A5039024566 @default.
- W4282930737 creator A5053398750 @default.
- W4282930737 creator A5070605844 @default.
- W4282930737 creator A5078993681 @default.
- W4282930737 date "2022-05-01" @default.
- W4282930737 modified "2023-09-26" @default.
- W4282930737 title "[Inflammation during COVID-19]." @default.
- W4282930737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35657183" @default.
- W4282930737 hasPublicationYear "2022" @default.
- W4282930737 type Work @default.
- W4282930737 citedByCount "0" @default.
- W4282930737 crossrefType "journal-article" @default.
- W4282930737 hasAuthorship W4282930737A5015363411 @default.
- W4282930737 hasAuthorship W4282930737A5016246504 @default.
- W4282930737 hasAuthorship W4282930737A5026753610 @default.
- W4282930737 hasAuthorship W4282930737A5035825833 @default.
- W4282930737 hasAuthorship W4282930737A5039024566 @default.
- W4282930737 hasAuthorship W4282930737A5053398750 @default.
- W4282930737 hasAuthorship W4282930737A5070605844 @default.
- W4282930737 hasAuthorship W4282930737A5078993681 @default.
- W4282930737 hasConcept C126322002 @default.
- W4282930737 hasConcept C203014093 @default.
- W4282930737 hasConcept C2776252253 @default.
- W4282930737 hasConcept C2776914184 @default.
- W4282930737 hasConcept C2778382381 @default.
- W4282930737 hasConcept C2778384902 @default.
- W4282930737 hasConcept C2779134260 @default.
- W4282930737 hasConcept C2779613421 @default.
- W4282930737 hasConcept C71924100 @default.
- W4282930737 hasConceptScore W4282930737C126322002 @default.
- W4282930737 hasConceptScore W4282930737C203014093 @default.
- W4282930737 hasConceptScore W4282930737C2776252253 @default.
- W4282930737 hasConceptScore W4282930737C2776914184 @default.
- W4282930737 hasConceptScore W4282930737C2778382381 @default.
- W4282930737 hasConceptScore W4282930737C2778384902 @default.
- W4282930737 hasConceptScore W4282930737C2779134260 @default.
- W4282930737 hasConceptScore W4282930737C2779613421 @default.
- W4282930737 hasConceptScore W4282930737C71924100 @default.
- W4282930737 hasIssue "5-6" @default.
- W4282930737 hasLocation W42829307371 @default.
- W4282930737 hasOpenAccess W4282930737 @default.
- W4282930737 hasPrimaryLocation W42829307371 @default.
- W4282930737 hasRelatedWork W10933767 @default.
- W4282930737 hasRelatedWork W12645252 @default.
- W4282930737 hasRelatedWork W14540105 @default.
- W4282930737 hasRelatedWork W16026736 @default.
- W4282930737 hasRelatedWork W17042839 @default.
- W4282930737 hasRelatedWork W18243675 @default.
- W4282930737 hasRelatedWork W19758746 @default.
- W4282930737 hasRelatedWork W20005122 @default.
- W4282930737 hasRelatedWork W415215 @default.
- W4282930737 hasRelatedWork W346155 @default.
- W4282930737 hasVolume "77" @default.
- W4282930737 isParatext "false" @default.
- W4282930737 isRetracted "false" @default.
- W4282930737 workType "article" @default.